ClinicalTrials.gg
RecruitingNCT07729787ADMP-CFUpdated Jul 28, 2026

Autogenic Drainage Versus Mechanical Percussion in Children With Cystic Fibrosis

An interventional study of Autogenic Drainage and Mechanical Percussion in Cystic Fibrosis (CF), sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effects of autogenic drainage and mechanical percussion on lung function, dyspnea, and quality of life in children with cystic fibrosis.

The main questions it aims to answer are:

  • Does autogenic drainage improve lung function more effectively than mechanical percussion in children with cystic fibrosis?
  • Does autogenic drainage reduce dyspnea (breathlessness) more effectively than mechanical percussion?
  • Does autogenic drainage improve health-related quality of life more effectively than mechanical percussion?

Researchers will compare autogenic drainage with mechanical percussion to determine which airway clearance technique provides greater benefits for children with cystic fibrosis.

Participants will:

  • Be randomly assigned to receive either autogenic drainage or mechanical percussion therapy.
  • Participate in supervised treatment sessions five times per week for six weeks.
  • Undergo assessments of lung function using spirometry (FEV₁ and FVC), dyspnea using the Modified Borg Dyspnea Scale, and quality of life using the Cystic Fibrosis Questionnaire-Revised (CFQ-R) before and after the intervention period.

The findings of this study may help identify the most effective airway clearance technique for improving respiratory health and quality of life in children with cystic fibrosis.

Read the detailed description

Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Dysfunction of the CFTR protein leads to impaired chloride and water transport across epithelial surfaces, resulting in the production of thick, dehydrated secretions in multiple organ systems, particularly the respiratory tract. The accumulation of viscous mucus within the airways contributes to chronic airway obstruction, recurrent pulmonary infections, persistent inflammation, progressive lung damage, and declining respiratory function. Despite advances in pharmacological treatment and supportive care, pulmonary complications remain the leading cause of morbidity and mortality in individuals with cystic fibrosis.

Airway clearance therapy is a fundamental component of respiratory management in patients with CF. The primary objective of airway clearance techniques (ACTs) is to mobilize and remove retained airway secretions, thereby improving ventilation, reducing airway obstruction, minimizing infection risk, preserving lung function, and enhancing quality of life. Various ACTs are available and are routinely incorporated into multidisciplinary CF care programs. However, determining the most effective airway clearance strategy remains challenging because patient responses vary and comparative evidence among techniques is often limited.

Autogenic drainage (AD) is an airway clearance technique based on controlled breathing at different lung volumes. The technique consists of three phases: unsticking, collecting, and evacuating secretions. Through carefully regulated inspiratory and expiratory airflow, AD promotes mucus mobilization from peripheral airways toward central airways where it can be effectively expectorated. Because the technique relies on self-regulated breathing rather than external mechanical forces, it may improve patient comfort, encourage independence, and facilitate long-term adherence. Previous studies have suggested that AD may improve pulmonary function, reduce airway resistance, enhance mucus clearance, and improve patient satisfaction. Nevertheless, evidence in pediatric populations remains limited.

Mechanical percussion is another commonly utilized airway clearance intervention in cystic fibrosis management. This technique employs rhythmic mechanical vibrations or percussion applied externally to the thoracic cage to loosen mucus adhered to airway walls. Mechanical percussion aims to facilitate mucus mobilization and subsequent clearance from the respiratory tract. The technique is frequently used in pediatric respiratory rehabilitation because it requires minimal active participation from younger children and can be administered by healthcare professionals or caregivers. Several studies have reported beneficial effects of mechanical percussion on secretion clearance and respiratory status. However, concerns regarding comfort, treatment burden, and long-term adherence have led clinicians to explore alternative airway clearance approaches.

Although both autogenic drainage and mechanical percussion are widely used in clinical practice, direct comparisons between these interventions in children with cystic fibrosis are scarce. Existing studies often include mixed age groups, employ heterogeneous outcome measures, or focus primarily on short-term physiological responses. Furthermore, limited evidence is available regarding their comparative effects on patient-centered outcomes such as dyspnea and health-related quality of life. Consequently, there remains uncertainty regarding which intervention provides superior clinical benefits for pediatric patients with CF.

The present study is designed to address this gap in the literature by directly comparing autogenic drainage and mechanical percussion in children diagnosed with cystic fibrosis. The study will employ a randomized clinical trial design to evaluate the relative effectiveness of these interventions on respiratory function, symptom burden, and quality of life. Participants meeting eligibility criteria will be recruited from tertiary care healthcare facilities and randomly allocated to one of two intervention groups.

Participants assigned to the Autogenic Drainage Group will receive therapist-guided autogenic drainage sessions. The intervention will be delivered according to standardized clinical procedures and will emphasize controlled breathing patterns designed to mobilize secretions from distal to proximal airways. Participants will receive training and supervision from qualified physiotherapists to ensure proper technique execution and treatment consistency.

Participants assigned to the Mechanical Percussion Group will receive standardized mechanical chest percussion therapy using a mechanical percussion device. Treatment protocols will follow established clinical recommendations to ensure consistent delivery and participant safety. Sessions will be administered by trained physiotherapists using appropriate positioning and device settings tailored to individual patient tolerance.

Both intervention groups will receive treatment five days per week for six consecutive weeks. Each treatment session will last approximately ten minutes and will be delivered under professional supervision to maximize adherence and ensure protocol fidelity. The frequency and duration of treatment were selected based on previous research demonstrating clinically meaningful improvements in respiratory outcomes among pediatric respiratory populations.

The primary outcomes of interest will include pulmonary function parameters measured using spirometry. Forced Expiratory Volume in One Second (FEV₁) and Forced Vital Capacity (FVC) will be assessed as objective indicators of respiratory function and airway clearance effectiveness. Spirometry remains the gold-standard method for evaluating pulmonary status in individuals with cystic fibrosis and provides clinically relevant information regarding disease progression and treatment response.

Secondary outcomes will include dyspnea and health-related quality of life. Dyspnea will be evaluated using the Modified Borg Dyspnea Scale, a validated subjective measure commonly used to assess perceived breathlessness in respiratory populations. Health-related quality of life will be assessed using the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a disease-specific instrument that evaluates the impact of cystic fibrosis on physical, emotional, and social functioning.

Outcome assessments will be conducted at baseline before intervention initiation and repeated following completion of the six-week treatment program. Statistical analyses will compare changes within each intervention group and between groups to determine whether one airway clearance technique demonstrates superior effectiveness.

The findings of this study are expected to contribute important evidence regarding airway clearance management in pediatric cystic fibrosis. By directly comparing autogenic drainage and mechanical percussion using objective and patient-reported outcome measures, the study may help clinicians make informed treatment decisions and optimize respiratory rehabilitation strategies. Improved understanding of the relative benefits of these interventions may ultimately enhance pulmonary health, reduce symptom burden, promote treatment adherence, and improve quality of life for children living with cystic fibrosis.

02

Conditions studied

  • Cystic Fibrosis (CF)

Keywords

  • Cystic Fibrosis
  • Autogenic Drainage
  • Mechanical Percussion
  • Airway Clearance Techniques
  • Chest Physiotherapy
  • Pulmonary Function
  • Spirometry
  • Dyspnea
03

In context

Cystic Fibrosis

1,619 studies on the registry are indexed under Cystic Fibrosis; 199 are open to participants now.

This study's planned enrollment of 32 is below the median of 36 across 1,051 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of cystic fibrosis (CF) through a sweat test or genetic testing.
  • Age between 6 and 12 years.
  • Clinically stable condition (no acute pulmonary exacerbation within the last 4 weeks).

Exclusion criteria

Exclusion Criteria:

  • History of thoracic surgery.
  • Active hemoptysis.
  • Severe physical or cognitive disabilities limiting participation in the intervention or assessments.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Autogenic Drainage Group

    Participants assigned to this arm will receive therapist-guided autogenic drainage, an airway clearance technique that uses controlled breathing at different lung volumes to mobilize secretions from peripheral to central airways. Treatment sessions will be administered five times per week for six weeks, with each session lasting approximately 10 minutes under physiotherapist supervision.

    Procedure: Autogenic Drainage

  • Experimental
    Mechanical Percussion Group

    Participants assigned to this arm will receive mechanical chest percussion therapy using a high-frequency percussion device to facilitate airway secretion clearance. Treatment sessions will be administered five times per week for six weeks, with each session lasting approximately 10 minutes under physiotherapist supervision.

    Device: Mechanical Percussion

Interventions

  • ProcedureAutogenic Drainage

    Autogenic drainage is a breathing-based airway clearance technique designed to mobilize and remove bronchial secretions. Participants will receive therapist-guided autogenic drainage sessions consisting of controlled breathing at low, medium, and high lung volumes to facilitate mucus movement from peripheral to central airways. Treatment sessions will be conducted under physiotherapist supervision for approximately 10 minutes per session, five times per week, for six weeks.

    Also known as: Airway Clearance Technique AD

  • DeviceMechanical Percussion

    Mechanical percussion is an airway clearance intervention that utilizes a mechanical percussion device to generate rhythmic vibrations over the chest wall to loosen and mobilize pulmonary secretions. Participants will receive supervised mechanical percussion therapy for approximately 10 minutes per session, five times per week, for six weeks. Treatment will be delivered according to standardized clinical procedures, with device settings adjusted to participant tolerance and clinical response.

    Also known as: Mechanical Chest Percussion Chest Percussion Therapy High-Frequency Percussion Therapy

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in One Second (FEV₁)

    Change in Forced Expiratory Volume in one second (FEV₁) measured using spirometry and reported in liters (L). Higher values indicate improved pulmonary function.

    Time frame: Baseline (Week 0) and post-intervention (Week 6).

  2. Forced Vital Capacity (FVC)

    Change in Forced Vital Capacity (FVC) measured using spirometry and reported in liters (L). Higher values indicate improved pulmonary function.

    Time frame: Baseline (Week 0) and post-intervention (Week 6).

  3. Dyspnea

    Change in dyspnea severity measured using the Modified Borg Dyspnea Scale (0-10). Lower scores indicate reduced dyspnea and clinical improvement.

    Time frame: Baseline (Week 0) and post-intervention (Week 6).

Secondary outcomes

  1. Cystic Fibrosis Questionnaire-Revised (CFQ-R) Total Score

    Change in health-related quality of life measured using the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: Baseline (Week 0) and post-intervention (Week 6).

07

Study locations

1 of 1 sites recruiting
  • Nishter Hospital Multan
    Multan Khurd, Punjab Province 59300, Pakistan
    Recruiting
    • Humera Ayub, MS CPPT · Contacthumera.ayub@riphah.edu.pk · +923045938096
    • Muhammad Farhan Faiz, MS-CPPT · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data (IPD) will not be shared because the study involves a small sample of pediatric participants with cystic fibrosis, and sharing de-identified data may still pose a risk of participant re-identification. Furthermore, the informed consent obtained from participants and their guardians did not include provisions for public sharing of individual-level data. Only aggregate study results will be reported to protect participant confidentiality and privacy.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07729787
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jun 14, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Imran Amjad, PhD
Contact
imran.amjad@riphah.edu.pk
03324390125
Humera Ayub, MS-CPPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion